These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26271040)

  • 1. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
    Kovarova M; Council OD; Date AA; Long JM; Nochi T; Belshan M; Shibata A; Vincent H; Baker CE; Thayer WO; Kraus G; Lachaud-Durand S; Williams P; Destache CJ; Garcia JV
    PLoS Pathog; 2015 Aug; 11(8):e1005075. PubMed ID: 26271040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
    Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
    Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
    J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
    Cranston RD; Dezzutti CS; Siegel A; Engstrom J; Shetler C; Richardson-Harman N; Abebe KZ; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams P; Brand RM; Parikh UM; McGowan I
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):794-804. PubMed ID: 31146534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting rilpivirine for HIV prevention.
    Jackson A; McGowan I
    Curr Opin HIV AIDS; 2015 Jul; 10(4):253-7. PubMed ID: 26049950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine: The Key for Long-term Success.
    Viciana P
    AIDS Rev; 2017; 19(3):156-166. PubMed ID: 29066858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Creelman B; Moyo Y; Lachau-Durand S; Niemeijer N; Williams P; McCarthy HO; Zehrung D; Donnelly RF
    Adv Healthc Mater; 2019 May; 8(9):e1801510. PubMed ID: 30838804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
    Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
    PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.
    Kovarova M; Shanmugasundaram U; Baker CE; Spagnuolo RA; De C; Nixon CC; Wahl A; Garcia JV
    J Antimicrob Chemother; 2016 Nov; 71(11):3185-3194. PubMed ID: 27494916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs.
    Surve DH; Jindal AB
    J Control Release; 2020 Aug; 324():379-404. PubMed ID: 32461114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
    Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
    HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.